Q-omics provides the consensus-scored MIR4500HG profile across patient tissues and cancer cell-line models. MIR4500HG expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, MIR4500HG is differentially expressed in 8, with the highest sampling consensus in THCA. Additionally, MIR4500HG RNA expression shows 9,970 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KIRP, THCA, and TGCT as cancer lineages where MIR4500HG shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR4500HG — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR4500HG survival associations across molecular data types. MIR4500HG RNA expression shows survival associations in the most cancer types (20). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR4500HG RNA expression–survival associations across cancer types. High MIR4500HG expression shows unfavorable associations in KICH, DLBC and MESO, but favorable associations in KIRP, LGG and HNSC. The KIRP Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .009). Together, the overview and detailed table identify KIRP as the clearest survival context for MIR4500HG RNA expression.
This table summarizes MIR4500HG tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for MIR4500HG. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR4500HG shows lower tumor expression in THCA, KICH, UCEC and READ and higher tumor expression in KIRP and KIRC. The THCA box plot shows higher MIR4500HG RNA expression in normal versus tumor tissue (log2 FC = −0.251, t-test p < 0.001).
This table shows molecular features associated with MIR4500HG in patient tissues and cancer cell lines. In patient samples, MIR4500HG shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
